The primary treatment for Parkinson's disease is dopaminergic stimulation. Although levodopa has historically been administered orally, maintaining a predictable plasma concentration of the drug is challenging. As a result, enteral administration of carbidopa/levodopa (Duopa) has emerged as a promising tool in the treatment of the disease. This requires placement of an enteric catheter, two of which have been approved by the Food and Drug Administration for delivery of Duopa. The approved tubes are placed using the "peroral" or "pull" technique, a method traditionally requiring endoscopy. This technical note describes placement of the AbbVie PEG-J tube by means of the peroral route while utilizing only sonographic and fluoroscopic guidance. After placing an orogastric tube and achieving percutaneous access to the stomach under fluoroscopic visualization, a snare catheter is advanced through the percutaneous access into the stomach. The orogastric tube is engaged with the snare and retracted, bringing the attached snare with it to the mouth. The AbbVie PEG tube is attached to the snare, pulled back down the esophagus and into the stomach before being retracted through the percutaneous access to the skin. Finally, the AbbVie J tube is advanced through the gastrostomy tube into the proximal jejunum and attached with the provided connectors. As demonstrated, the AbbVie PEG-J tube can be placed safely and effectively using a percutaneous image-guided technique without the use of an endoscope.
A lthough many treatment options exist, the treatment of Parkinson's disease has primarily consisted of dopaminergic stimulation achieved with oral levodopa ( 1 ). More recently, direct enteral administration of carbidopa/levodopa (Duopa) has been shown to off er distinct advantages (2) (3) (4) . To facilitate enteral administration, a transgastric jejunal tube is needed. Th e two tubes approved for delivery of Duopa are the AbbVie™ percutaneous endoscopic gastrostomy (PEG)-jejunostomy feeding tube (J tube) and EndoVive™ PEG-J tube. Both of these tubes are retained by an internal phalange necessitating peroral placement, historically achieved endoscopically. We describe a technique to place the AbbVie PEG-J tube under fl uoroscopy without endoscopy. By enabling the procedure to be performed by more providers, patient access to this promising treatment will be improved. 
BACKGROUND
In the United States, approximately 60,000 people are diagnosed with Parkinson's disease each year, and as many as 1 million people are currently living with the disease. Oral levodopa, the mainstay of treatment, is absorbed in the proximal third of the small intestine. As such, its pharmacokinetics are largely dependent on gastric emptying, which can be delayed in these patients, resulting in an unpredictable levodopa plasma concentration ( 2, 4 ) . Direct enteral administration of Duopa has been shown to decrease this variation in plasma concentration, resulting in reduced "off " time, improved motor performance, and a better quality of life ( 2, 3, 5 ).
TECHNIQUE
Our patient was seen in the interventional radiology clinic, where risks, benefi ts, and postprocedure care were explained. Informed consent was obtained. Th e patient was instructed to ingest barium (8 ounces) the night before the procedure and to fast for 6 hours prior to the procedure. On the day of the procedure, the patient was placed supine, and an oral bite block (EnCompas) was inserted. Sedation was achieved with intravenous midazolam, fentanyl, and diphenhydramine. One gram of intravenous cefazolin was given as antibiotic prophylaxis. Th e liver was marked on the skin with ultrasound to avoid its inadvertent transgression.
A Corpak orogastric tube (Corpak Medsystems, Buff alo Grove, IL) was placed through the oral bite block , advanced into the stomach, and used to insuffl ate the stomach with room air. Lidocaine (1%) was administered locally, and a 19-gauge Chiba needle (Cook Medical, Bloomington, IN) was advanced into the mid-body of the stomach directed toward the pylorus under intermittent fl uoroscopic guidance. Care was taken to avoid inadvertent puncture of the liver or barium-fi lled colon. A small incision was made at the puncture site.
Th e needle was exchanged for a 6 French Pinnacle sheath (Terumo Medical, Somerset, NJ) over a 0.035-inch Bentson wire (Boston Scientifi c, Marlborough, MA) using standard Seldinger technique. An EnSnare device (Merit Medical, South Jordan, UT) was advanced through the sheath and was used to snare the previously placed orogastric tube in the distal gastric antrum where the potential space was smallest. Next, the orogastric tube was retracted at the bite block, pulling the connected snare catheter up the esophagus and out of the mouth ( Figure 1 ) . Th e AbbVie PEG fi xation loop was attached to the snare, which was pulled back into the stomach and out through the percutaneous gastric access site until the internal retention plate of the tube apposed the inner gastric wall.
Th e externalized tapered tip of the PEG tube was then cut off to allow the coaxial insertion of a 6 French Cobra catheter (Cook Medical, Bloomington, IN), which was advanced into the proximal jejunum over a 0.035-inch exchange length hydrophilic Glidewire (Terumo Medical, Somerset, NJ). Th e Cobra catheter was exchanged for the AbbVie J tube over the wire, facilitated by use of a small amount of nonpetroleum gel (Sterile Aquasonic, Parker Laboratories, Fairfi eld, NJ). Th e wire was removed, the position of the tube was confi rmed fl uoroscopically, and the J tube was attached to the gastrostomy tube using the supplied connectors, as per the manufacturer's instructions ( Figure 2 ) . Fluoroscopy time was 10.5 minutes.
A small sterile dressing was applied. Th e patient was observed in the interventional radiology observation suite for 1 hour after the procedure and instructed to follow up in the interventional radiology clinic in 1 week in conjunction with a neurology appointment.
DISCUSSION
To our knowledge, this is the fi rst described technique that allows for placement of the AbbVie PEG-J tube with an internal phalange without the use of endoscopy. Fluoroscopic visualization of the opacifi ed bowel ensures that the large bowel will not be perforated. We have also found that using fl uoroscopic guidance during percutaneous gastric access results in a favorable "downstream" orientation of the gastrostomy tube, which facilitates snaring of the orogastric tube in the gastric antrum. It also results in an optimal "lie" of the J tube, which courses naturally across the pylorus into the duodenum without the tendency to kink or coil in the stomach. Th e described technique can be performed very quickly without any identifi ed increased risk.
Jejunal administration of dopaminergic agents for the treatment of Parkinson's disease is a very promising potential treatment option for patients affl icted with this disease. As one of the two approved transgastric jejunal tubes, AbbVie PEG-J facilitates this treatment, as it is specifi cally designed to connect to the Duopa pump. Peroral image-guided gastrostomy placement has been proven to be a highly safe and eff ective technique ( 6 ). Although there is slight variation in the technique used to place the AbbVie PEG-J compared with previously described techniques, this particular tube can be placed with little difficulty in the interventional radiology suite. Placement of the AbbVie PEG-J tube under direct fl uoroscopic guidance is a safe and eff ective procedure that is well suited for the skill set of an interventional radiologist. 
